Read this commentary for a practical discussion of how neoadjuvant and adjuvant treatment is being increasingly personalized across HRpositive HER2positive and triplenegative earlystage breast cancer The activity highlights how patient goals comorbidities tolerance and shared decisionmaking shape therapy selection while also addressing the evolving treatment landscape including new HER2positive approvals such as trastuzumab deruxtecan in curativeintent care It also reviews how emerging evidence residual disease status biomarker findings and clinical trial options can help healthcare professionals tailor individualized treatment plans and keep pace with a rapidly changing standard of care
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
98% of listed courses are free
294 of a sample of 300 are free · 531 courses listed here.
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Clinical Informatics
- Clinician Wellness & Burnout
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Geriatric Psychiatry
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Infectious Disease
- Laryngology
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Neonatal-Perinatal Medicine
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Obstetrics & Gynecology
- Otology & Neurotology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Hematology-Oncology
- Pediatric Infectious Diseases
- Pediatric Otolaryngology
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 0.25 credits
- MOC · Up to 0.25 points
- Commercial Support
-
ReleasedJul 15, 2026
-
Last day to claim creditJan 15, 2027 3 months left
-
PRIME Education, Inc. (PRIME®) Personalizing Adjuvant Therapy in HR+/HER2- Early-Stage Breast Cancer Based on Latest Evidence and Patient-Specific Factors
-
Efficient CME, CME Outfitters, LLC Individualizing the Journey Through Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Testing, Treatments, and Real Patient Experiences in PI3K-Pathway Altered Disease
-
National Comprehensive Cancer Network Team Strategies for Overcoming Challenges to Guideline-Concordant Care of High-Risk HR-Positive/HER2-Negative Early Breast Cancer
-
Clinical Care Options, LLC (dba Decera Clinical Education) Optimizing Neoadjuvant Treatment in HER2+ Early-Stage Breast Cancer
-
Clinical Care Options, LLC (dba Decera Clinical Education) Evolving Treatment Landscape for HER2-Positive Early Breast Cancer
-
Clinical Care Options, LLC (dba Decera Clinical Education) Optimizing Treatment Sequencing in HER2-Positive Metastatic Breast Cancer
